Items by Leese, Mathew

Leese, M. P., Jourdan, F., Dohle, W., Kimberley, M. R., Thomas, M. P., Bai, R. L., Hamel, E., Ferrandis, E. and Potter, B. V. L., 2012. Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors. ACS Medicinal Chemistry Letters, 3 (1), pp. 5-9.

Jourdan, F., Leese, M. P., Dohle, W., Ferrandis, E., Newman, S. P., Chander, S., Purohit, A. and Potter, B. V. L., 2011. Structure-activity relationships of C-17-substituted estratriene-3-O-sulfamates as anticancer agents. Journal of Medicinal Chemistry, 54 (13), pp. 4863-4879.

Leese, M. P., Jourdan, F., Ferrandis, E., Regis-Lydi, S., Kasprzyk, P. G., Stengel, C., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Optimisation of tetrahydroisoquinoline based microtubule disruptors as anti-cancer agents. EJC Supplements, 8 (7), p. 141.

Leese, M. P., Jourdan, F., Kimberley, M. R., Cozier, G. E., Thiyagarajan, N., Stengel, C., Regis-Lydi, S., Foster, P. A., Newman, S. P., Acharya, K. R., Ferrandis, E., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Chimeric microtubule disruptors. Chemical Communications, 46 (17), pp. 2907-2909.

Cozier, G. E., Leese, M. P., Lloyd, M. A., Baker, M. D., Thiyagarajan, N., Acharya, K. R. and Potter, B. V. L., 2010. Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors. Biochemistry, 49 (16), pp. 3464-3476.

Jourdan, F., Leese, M. P., Dohle, W., Hamel, E., Ferrandis, E., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-Methoxyestradiol-3,17-O,O-bis-sulfamate. Journal of Medicinal Chemistry, 53 (7), pp. 2942-2951.

Stengel, C., Newman, S. P., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2010. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. British Journal of Cancer, 102 (2), pp. 316-324.

Foster, P. A., Ho, Y. T., Newman, S. P., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2009. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Research, 29 (10), pp. 3751-3758.

Parsons, M. F. C., Foster, P. A., Chander, S. K., Jhalli, R., Newman, S. P., Leese, M. P., Potter, B. V. L., Purohit, A. and Reed, M. J., 2008. The in vivo properties of STX243: A potent angiogenesis inhibitor in breast cancer. British Journal of Cancer, 99 (9), pp. 1433-1441.

Newman, S. P., Foster, P. A., Stengel, C., Day, J. M., Ho, Y. T., Judde, J.-G., Lassalle, M., Prevost, G., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clinical Cancer Research, 14 (2), pp. 597-606.

Foster, P. A., Ho, Y. T., Newman, S. P., Kasprzyk, P. G., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Research and Treatment, 111 (2), pp. 251-260.

Tagg, S. L. C., Foster, P. A., Leese, M. P., Potter, B. V. L., Reed, M. J., Purohit, A. and Newman, S. P., 2008. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. British Journal of Cancer, 99 (11), pp. 1842-1848.

Foster, P. A., Stengel, C., Ali, T., Leese, M. P., Potter, B. V. L., Reed, M. J., Purohit, A. and Newman, S. P., 2008. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Research, 28 (3A), pp. 1483-1491.

Foster, P. A., Newman, S. P., Leese, M. P., Bernetiere, S., Diolez, C., Camara, J., Hacher, B., Baronnet, M.-M., Ali, T., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. A new micronized formulation of 2-methoxyestradiol- bis -sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Research, 28 (2A), pp. 577-581.

Jourdan, F., Bubert, C., Leese, M. P., Smith, A., Ferrandis, E., Regis-Lydi, S., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: synthesis, in vitro evaluation and computational modelling. Organic and Biomolecular Chemistry, 6 (22), pp. 4108-4119.

Leese, M. P., Jourdan, F. L., Gaukroger, K., Mahon, M. F., Newman, S. P., Foster, P. A., Stengel, C., Regis-Lydi, S., Ferrandis, E., Di Fiore, A., De Simone, G., Supuran, C. T., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. Journal of Medicinal Chemistry, 51 (5), pp. 1295-1308.

Chander, S. K., Foster, P. A., Leese, M. P., Newman, S. P., Potter, B. V. L., Purohit, A. and Reed, M. J., 2007. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. British Journal of Cancer, 96 (9), pp. 1368-1376.

Newman, S. P., Foster, P. A., Ho, Y. T., Day, J. M., Raobaikady, B., Kasprzyk, P. G., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2007. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. British Journal of Cancer, 97 (12), pp. 1673-1682.

Leese, M. P., Leblond, B., Smith, A., Newman, S. P., Di Fiore, A., De Simone, G., Supuran, C. T., Purohit, A., Reed, M. J. and Potter, B. V. L., 2006. 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents : synthesis, in vitro SAR, protein crystallography, and in vivo activity. Journal of Medicinal Chemistry, 49 (26), pp. 7683-7696.

Newman, S. P., Ireson, C. R., Tutill, H. J., Day, J. M., Parsons, M. F.C., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2006. The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Research, 66 (1), pp. 324-330.

Leese, M. P., Hejaz, H. A. M., Mahon, M. F., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2005. A-Ring-Substituted Estrogen-3- O -sulfamates : potent multitargeted anticancer agents. Journal of Medicinal Chemistry, 48 (16), pp. 5243-5256.

Leese, M. P., Hejaz, H. A. M., Mahon, M. F., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2005. A-ring-substituted estrogen-3- 0 -sulfamates: potent multitargeted anticancer agents. Journal of Medicinal Chemistry, 48, pp. 5243-5256.

Leese, M. P., Leblond, B., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2005. Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3- 0 -sulfamates. Steroid Biochemistry & Molecular Biology, 94 (1), pp. 239-251.

Raobaikady, B., Reed, M. J., Leese, M. P., Potter, B. V. L. and Purohit, A., 2005. Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono - and bis -3- 0 -sulphamates. International Journal of Cancer, 117 (1), pp. 150-159.

Purohit, A., Ghilchik, M. W., Leese, M. P., Potter, B. V. L. and Reed, M. J., 2005. Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-0 -sulphamate in fibroblasts derived from normal and malignant breast tissues. Steroid Biochemistry & Molecular Biology, 94 (1), pp. 167-172.

Leese, M. P., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2004. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. Bioorganic & Medicinal Chemistry Letters, 14, pp. 3135-3138.

Reed, J. E., Woo, L. W. L., Robinson, J. J., Leblond, B., Leese, M. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2004. 2-Difluoromethyloestrone 3-0-sulphamate, a highly potent steroid sulphatase inhibitor. Biochemical and Biophysical Research Communications, 317 (1), pp. 169-175.

Wood, L., Leese, M. P., Mouzakiti, A., Purohit, A., Potter, B. V. L., Reed, M. J. and Packham, G., 2004. 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases. Apoptosis, 9 (3), pp. 323-332.

Newman, S. P., Leese, M. P., Purohit, A., James, D. R. C., Rennie, C. E., Potter, B. V. L. and Reed, M. J., 2004. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. International Journal of Cancer, 109 (4), pp. 533-540.

Suzuki, R. N., Newman, S. P., Purohit, A., Leese, M. P., Potter, B. V. L. and Reed, M. J., 2003. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. Steroid Biochemistry & Molecular Biology, 84 (2), pp. 269-278.

Raobaikady, B., Purohit, A., Chander, S. K., Woo, L. W. L., Leese, M. P., Potter, B. V. L. and Reed, M. J., 2003. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. Steroid Biochemistry & Molecular Biology, 84 (2), pp. 351-358.

Purohit, A., Woo, L. W. L., Chander, S. K., Newman, S. P., Ireson, C., Ho, Y., Grasso, A., Leese, M. P., Potter, B. V. L. and Reed, M. J., 2003. Steroid sulphatase inhibitors for breast cancer therapy. Steroid Biochemistry & Molecular Biology, 86 (3), pp. 423-432.

Ho, Y. T., Newman, S. P., Purohit, A., Leese, M. P., Potter, B. V. L. and Reed, M. J., 2003. The effects of 2-methyl oestrogens and their sukphamaoylated derivatives in conjunction with TNF-α on endothelial and fibroblast cell growth, morphology and apoptosis. Steroid Biochemistry & Molecular Biology, 86, pp. 189-196.

Day, J. M., Newman, S. P., Comninos, A., Solomon, C., Purohit, A., Leese, M. P., Potter, B. V. L. and Reed, M. J., 2003. The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. Steroid Biochemistry & Molecular Biology, 84 (2-3), pp. 317-325.

Wood, L., Leese, M. P., Leblond, B., Woo, L. W. L., Ganeshapillai, D., Purohit, A., Reed, M. J., Potter, B. V. L. and Packham, G., 2002. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. Anti-Cancer Drug Design, 16 (4), pp. 209-215.